Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?

Idiopathic pulmonary fibrosis is by definition a progressive disease with high mortality, thus, clinical practice guidelines would recommend treatment at diagnosis. Based on US and UK epidemiologic studies, IPF has an average life expectancy of 3-4 years without antifibrotic treatment. Furthermore, ...

Yes, but not often. It always seems odd to me that patients and some providers want to wait until there's progression.

I had a mentor who told me there were three certainties in life: "Death, taxes, and IPF progresses." Clearly meant for comedic effect, but it's pretty true. If a patient doesn't prog...